Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03637803
Title MRx0518 and Pembrolizumab Combination Study
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors 4DPharma PLC
Indications

melanoma

lung non-small cell carcinoma

renal cell carcinoma

urinary bladder cancer

Therapies

MRx0518 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.